- Home
- UTSI vs BOLD Comparison
UTSI vs BOLD Comparison
Compare UTSI & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UTSI
- BOLD
- Stock Information
- Founded
- UTSI 1991
- BOLD 2018
- Country
- UTSI China
- BOLD United States
- Employees
- UTSI N/A
- BOLD N/A
- Industry
- UTSI Telecommunications Equipment
- BOLD
- Sector
- UTSI Telecommunications
- BOLD
- Exchange
- UTSI Nasdaq
- BOLD Nasdaq
- Market Cap
- UTSI 24.9M
- BOLD 24.4M
- IPO Year
- UTSI 2000
- BOLD 2024
- Fundamental
- Price
- UTSI $2.28
- BOLD $1.14
- Analyst Decision
- UTSI
- BOLD Buy
- Analyst Count
- UTSI 0
- BOLD 4
- Target Price
- UTSI N/A
- BOLD $4.00
- AVG Volume (30 Days)
- UTSI 6.0K
- BOLD 78.3K
- Earning Date
- UTSI 08-29-2025
- BOLD 11-06-2025
- Dividend Yield
- UTSI N/A
- BOLD N/A
- EPS Growth
- UTSI N/A
- BOLD N/A
- EPS
- UTSI N/A
- BOLD N/A
- Revenue
- UTSI $9,793,000.00
- BOLD N/A
- Revenue This Year
- UTSI N/A
- BOLD N/A
- Revenue Next Year
- UTSI N/A
- BOLD N/A
- P/E Ratio
- UTSI N/A
- BOLD N/A
- Revenue Growth
- UTSI N/A
- BOLD N/A
- 52 Week Low
- UTSI $1.84
- BOLD $1.00
- 52 Week High
- UTSI $3.22
- BOLD $4.72
- Technical
- Relative Strength Index (RSI)
- UTSI 44.88
- BOLD 47.21
- Support Level
- UTSI $2.15
- BOLD $1.13
- Resistance Level
- UTSI $2.55
- BOLD $1.19
- Average True Range (ATR)
- UTSI 0.15
- BOLD 0.04
- MACD
- UTSI -0.03
- BOLD 0.00
- Stochastic Oscillator
- UTSI 19.21
- BOLD 44.44
About UTSI UTStarcom Holdings Corp.
UTStarcom Holdings Corp is providing telecommunication network products, solutions and services. It focus on delivering carrier-class packet optical, network synchronization and broadband access (both wireless and fixed line) products and solutions, coupled with Software Defined Networking (SDN) platform, optimized for mobile backhaul, metro aggregation, broadband access and value added services. The business activity of the firm is operated through the Equipment and Service segment. The Equipment segment is focused on equipment sales, including network infrastructure and application products, and the Service segment is engaged in providing services and support of equipment products and also the new operational support. Key revenue is generated from Equipment segment.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.